* In the Phase III RAINBOW study, despite marginally missing statistical
significance for the primary endpoint of demonstrating superiority of
Lucentis(®) to laser surgery, Lucentis was shown to be an efficacious, safe
and well-tolerated treatment for infants with ROP [1]
significance for the primary endpoint of demonstrating superiority of
Lucentis(®) to laser surgery, Lucentis was shown to be an efficacious, safe
and well-tolerated treatment for infants with ROP [1]
* Laser surgery, the current standard of care for ROP in infants, destroys
diseased retinal tissue responsible for elevated vascular endothelial growth
factor (VEGF) whereas Lucentis is an anti-VEGF that directly targets and
reduces VEGF[2]
diseased retinal tissue responsible for elevated vascular endothelial growth
factor (VEGF) whereas Lucentis is an anti-VEGF that directly targets and
reduces VEGF[2]
* With 80% of patients achieving treatment success with 0.2mg Lucentis versus
66% with laser, these data are clinically relevant[1]
66% with laser, these data are clinically relevant[1]
* Novartis plans to file ex-US for a new indication in ROP to bring
transformative treatment to premature infants facing severe vision loss –
the first anti-VEGF product to seek an ROP indication
transformative treatment to premature infants facing severe vision loss –
the first anti-VEGF product to seek an ROP indication
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.